IRIS
JAFFRAIN, MARIE LISE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.961
EU - Europa 1.913
AS - Asia 822
AF - Africa 14
OC - Oceania 11
Continente sconosciuto - Info sul continente non disponibili 7
SA - Sud America 3
Totale 5.731
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.945
IE - Irlanda 661
CN - Cina 415
TR - Turchia 313
SE - Svezia 298
IT - Italia 224
DE - Germania 202
GB - Regno Unito 170
UA - Ucraina 170
FI - Finlandia 88
FR - Francia 52
VN - Vietnam 50
BE - Belgio 19
IN - India 13
CA - Canada 12
CZ - Repubblica Ceca 11
SG - Singapore 11
AU - Australia 9
DZ - Algeria 9
EU - Europa 7
RU - Federazione Russa 6
IL - Israele 5
JP - Giappone 5
KR - Corea 4
BR - Brasile 3
MX - Messico 3
NL - Olanda 3
TN - Tunisia 3
NZ - Nuova Zelanda 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
BH - Bahrain 1
EG - Egitto 1
ES - Italia 1
HK - Hong Kong 1
HR - Croazia 1
ID - Indonesia 1
IQ - Iraq 1
IS - Islanda 1
KZ - Kazakistan 1
MA - Marocco 1
MD - Moldavia 1
MK - Macedonia 1
NO - Norvegia 1
PA - Panama 1
PL - Polonia 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 5.731
Salva come PNG Salva come JPEG
Città #
Jacksonville 698
Chandler 682
Dublin 661
Boardman 158
Izmir 148
Nanjing 124
San Mateo 124
Wilmington 102
Lawrence 98
Princeton 98
L’Aquila 90
New York 88
Ann Arbor 80
Ashburn 61
Dong Ket 48
Milan 42
Des Moines 39
Nanchang 39
Woodbridge 34
Dearborn 33
Shenyang 30
L'aquila 29
Hebei 27
Verona 27
Mountain View 25
Seattle 25
Jiaxing 24
Beijing 23
Kunming 23
Tianjin 21
San Francisco 18
Brussels 17
Los Angeles 17
Guangzhou 15
Munich 14
Changsha 13
Jinan 13
Shanghai 12
Brno 10
Toronto 10
Helsinki 9
Ningbo 9
Norwalk 9
Falls Church 8
Zhengzhou 8
Philadelphia 7
Pune 7
Changchun 6
Bremen 5
Paris 5
Singapore 5
Capistrello 4
Fremont 4
Melbourne 4
Rome 4
Taizhou 4
Tappahannock 4
Washington 4
Hefei 3
Lanzhou 3
Menlo Park 3
Mexico City 3
Padova 3
Sydney 3
Tokyo 3
Almere Stad 2
Aquila 2
Catanzaro 2
Chengdu 2
Edinburgh 2
Frankfurt am Main 2
Grafing 2
Haikou 2
Hangzhou 2
Hanoi 2
Houston 2
London 2
Redwood City 2
Reston 2
Torre del Greco 2
Aix-en-provence 1
Al Muharraq 1
Almaty 1
Antwerp 1
Atlanta 1
Auburn Hills 1
Berlin 1
Bratislava 1
Brussel 1
Buffalo 1
Canberra 1
Chieti 1
Chongqing 1
Christchurch 1
Clifton 1
Crowthorne 1
Dubai 1
East Boldon 1
Fairfield 1
Görwihl 1
Totale 4.017
Salva come PNG Salva come JPEG
Nome #
AHR over-expression in papillary thyroid carcinoma: clinical and molecular assessments in a series of Italian acromegalic patients with a long-term follow-up. 151
18F-DOPA PET/CT Physiological Distribution and Pitfalls: Experience in 215 Patients 106
L'acromégalie familiale: A propos d'une observation, revue de la littérature 100
X-linked acrogigantism syndrome: Clinical profile and therapeutic responses 89
Fractionated stereotactic radiotherapy for large and invasive non-functioning pituitary adenomas: long-term clinical outcomes and volumetric MRI assessment of tumor response. 85
High prevalence of AIP gene mutations following focused screening in young patients with sporadic pituitary macroadenomas. 80
Two familial giant pituitary adenomas associated with overweight: clinical, morphological and genetic features 80
Aryl Hydrocarbon Receptor Interacting Protein (AIP) Gene Mutations in Familial Isolated Pituitary Adenomas: Analysis in 73 Families 79
Clinical and genetic characterization of pituitary gigantism: An international collaborative study in 208 patients 78
Aggressive prolactinoma in a child related to germline mutation in the Aryl hydrocarbon receptor Interacting Protein (AIP) gene. 75
15 year-old boy with ocular palsy and headache. Invasive macroprolactinoma 75
Contenuto dei grassi nella dieta e rischio di insorgenza di carcinoma della mammella. 74
T2-weighted MRI signal predicts hormone and tumor responses to somatostatin analogs in acromegaly 73
De la génétique des adénomes hypophysaires 72
Clinical characterization of familial isolated pituitary adenomas 71
Marked improvement in cardiovascular function after successful transsphenoidal surgery in acromegalic patients 71
Effects of gonadal steroids on the growth of human pituitary adenomas in vitro 70
Impact of successful transsphenoidal surgery on cardiovascular risk factors in acromegaly 70
Downregulation of miR-410 targeting the cyclin B1 gene plays a role in pituitary gonadotroph tumors 69
Acute effects of octreotide, cabergoline and a combination of both drugs on GH secretion in acromegalic patients 68
Clinical and genetic features of familial pituitary adenomas 68
Prognostic Factors: Molecular Pathway – Tumour Suppressor Gene (MEN1) 68
The R304X mutation of the Aryl hydrocarbon receptor Interacting Protein (AIP) gene in familial isolated pituitary adenomas: mutational Hot-Spot or founder effect? 68
Expression of Epidermal Growth Factor in neoplastic pituitary cells: evidence for a role in corticotrophinoma cells 67
Beta-interferon, retinoids and tamoxifen as maintenance therapy in metastatic breast cancer. A pilot study 67
p16 (INK4a, MTS-1) gene polymorphism and methylation status in human pituitary tumors 67
Prevalence of hypertension in acromegalic patients: clinical measurement versus 24-hour ambulatory blood pressure monitoring 67
Relationship between blood pressure and glucose tolerance in acromegaly 66
Diagnosis and management of pituitary tumours in the elderly: a review based on personal experience and evidence of literature 66
Expression of Peroxisome Proliferator-Activated Receptor alpha (PPARα) in somatotropinomas: Relationship with Aryl hydrocarbon receptor Interacting Protein (AIP) and in vitro effects of fenofibrate in GH3 cells 66
Comparison of six-months therapy with octreotide versus lanreotide in acromegalic patients: a retrospective study 65
From resistant to aggressive and malignant prolactinomas: a translational approach 65
A constitutive active MAPK/ERK pathway due to BRAFV600E positively regulates AHR pathway in PTC 65
Acromegaly at diagnosis in 3173 patients from the Liège Acromegaly Survey (LAS) Database 65
Expression of aryl hydrocarbon receptor (AHR) and AHR-interacting protein in pitutuitary adenomas: pathological and clinical implications 64
Echocardiographic evidence for a direct effect of GH/IGF-I hypersecretion on cardiac mass and function in young acromegalics 64
Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: an international collaborative study. 64
HMGA1-pseudogene expression is induced in human pituitary tumors 64
Biochemical remission and recurrence rate of secreting pituitary adenomas after transsphenoidal adenomectomy: long-term endocrine follow-up results 63
Hyperplasia-adenoma sequence in pituitary tumorigenesis related to Aryl hydrocarbon receptor Interacting Protein gene mutation. 63
A critical re-appraisal of MIB-1 labelling index significance in a large series of pituitary tumours: secreting versus non-secreting adenomas 62
Cardiac effects of SR-Lanreotide, a slow-release somatostatin analog, in acromegalic patients 62
Dopamine D2 receptor gene polymorphisms and response to cabergoline therapy inpatients with prolactin-secreting pituitary adenomas 62
Somatic mosaicism underlies X-linked acrogigantism syndrome in sporadic male subjects 62
Il ruolo dell'endocrinologo nel trattamento delle lesioni della regione sellare 60
Familial pituitary adenomas. 60
Infusione sequenziale di GHRH 1-29NH2, LHRH e TRH per la valutazione della riserva ipofisaria: confronto con il Politest. 59
The genetics of pituitary adenomas 58
Macroprolactinomas as a cause of delayed puberty: a report of two cases and effects of medical therapy 57
Mutations in the aryl hydrocarbon receptor interacting protein gene are not highly prevalent among subjects with sporadic pituitary adenomas 57
Expression of Peroxisome Proliferator-Activated Receptor Alpha (PPARα) in Non-Somatotroph Pituitary Tumours and the Effects of PPARα Agonists on MMQ Cells 57
Two-year follow-up of acromegalic patients treated with slow release Lanreotide (30 mg) 56
Somatostatin analogues increase AIP expression in somatotropinomas, irrespective of Gsp mutations. 56
Genetic susceptibility in pituitary adenomas: from pathogenesis to clinical implications 55
Cyclin-dependent kinase inhibitor 1B (CDKN1B) gene variants in AIP mutation-negative familial isolated pituitary adenoma kindreds. 54
A standardised diagnostic approach to pituitary neuroendocrine tumours (PitNETs): a European Pituitary Pathology Group (EPPG) proposal 54
Influence of radiotherapy on long-term follow-up of clinically non-secreting pituitary adenomas 53
Surgical treatment and clinical outcome of GH-secreting adenomas in elderly patients 53
Evaluation of the adequacy of Levothyroxine replacement therapy in patients with central hypothyroidism 53
Variable pathological and clinical features of a large Brazilian family harboring a mutation in the aryl hydrocarbon receptor-interacting protein gene 53
HPLC determination of urinary catecholamines as a screening test for pheochromocytoma in a patient with medullary carcinoma of the thyroid. 52
Cellular receptors for sex steroids in human pituitary adenomas 52
Effect of 17β-estradiol, progesterone and tamoxifen on in vitro proliferation of human pituitary adenomas. Correlation with specific cellular receptors 52
Familial pituitary adenomas: from clinical practice to basic research 52
Long-term follow-up results of postoperative radiation therapy for Cushing's disease 51
Pituitary adenomas in young patients: when should we consider a genetic predisposition? 51
New insights in the pathogenesis of pituitary tumours 50
Radiotherapy for nonfunctioning pituitary adenomas: from conventional to modern stereotactic radiation techniques. 50
Le forme familiari di adenoma ipofisario 49
The long-term efficacy of conventional radiotherapy in patients with GH-secreting pituitary adenomas 48
A multivariable prediction model for pegvisomant dosing: Monotherapy and in combination with long-acting somatostatin analogues 48
Pituitary neuroendocrine tumors (PitNETs): nomenclature evolution, not clinical revolution 48
Growth hormone receptor variants and response to pegvisomant in monotherapy or in combination with somatostatin analogs in acromegalic patients: a multicenter study. 47
Visual improvement during octreotide therapy in a case of episellar meningioma 47
Human pituitary tumours express the bHLH transcription factors NeuroD1 and ASH1 46
Mir-23b and miR-130b expression is downregulated in pituitary adenomas 46
Hypophysitis 46
Surgical treatment of pituitary tumours in the elderly: clinical outcome and long-term follow-up 45
Epidermal growth factor (EGF)- binding sites in human pituitary adenomas 44
The Role of Aryl Hydrocarbon Receptor (AHR) and AHR-Interacting Protein (AIP) in the Pathogenesis of Pituitary Adenomas 44
Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients. 43
Hypophysitis and Granulomatous Pituitary Lesions in Systemic Diseases 43
Differential expression of neurogenins and NeuroD1 in human pituitary tumours 42
How to Classify Pituitary Neuroendocrine Tumors (PitNET)s in 2020 42
Are aggressive pituitary tumors and carcinomas two sides of the same coin? Pathologists reply to clinician’s questions 41
Evolving criteria for post-operative biochemical remission of acromegaly: can we achieve a definitive cure ? An audit of surgical results on a large series and a review of the literature 40
Giant prolactinomas presenting as skull base tumors 39
Fenofibrate has differential effects on cell proliferation and GH secretion in GH3 cells 39
Recurrence of GH-secreting pituitary adenomas during puberty in children with germline AIP mutations: a clinical challenge 37
Alternative Lengthening of Telomeres (ALT) and Telomerase Reverse Transcriptase Promoter Methylation in Recurrent Adult and Primary Pediatric Pituitary Neuroendocrine Tumors 37
Salivary gland tissues and derived primary and metastatic neoplasms: unusual pitfalls in the work-up of sellar lesions. A systematic review 36
Prevalence of silent acromegaly in prolactinomas (PASP): an Italian experience 35
Single dose irradiation of GH3 cells increase GH and PRL secretion in vitro 35
Stereotactic reirradiation with temozolomide in patients with recurrent aggressive pituitary tumors and pituitary carcinomas 34
Cardiovascular complications in pituitary gigantism (results of an international study) 34
Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016 32
Sellar and parasellar lesions in the transition age: a retrospective Italian multi-centre study 31
The prevalence of silent acromegaly in prolactinomas is very low 31
Sleep Disorders in Patients With Craniopharyngioma: A Physiopathological and Practical Update 27
Multivariable Prediction Model for Biochemical Response to First-Generation Somatostatin Receptor Ligands in Acromegaly 25
Totale 5.782
Salva come PNG Salva come JPEG
Categoria #
all - tutte 22.246
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 22.246
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020716 162 2 83 7 2 93 152 17 96 12 4 86
2020/2021826 8 88 0 89 97 30 98 11 112 33 172 88
2021/2022676 34 56 120 35 36 7 5 44 37 7 33 262
2022/20231.879 136 112 74 173 163 215 2 116 792 5 64 27
2023/2024528 159 29 19 69 33 136 9 13 2 15 12 32
2024/202532 32 0 0 0 0 0 0 0 0 0 0 0
Totale 5.840